Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Quantification of Thalamic Volume in Multiple Sclerosis: From the Multicenter INNI Dataset Towards the Clinical Application
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-002

Thalamic atrophy has been found since the earliest phases of MS. However, this measure is not included in clinical practice, due to the time-consuming manual segmentation and technical challenges.

To obtain a reliable segmentation of the thalamus in multiple sclerosis (MS) by comparing existing automatic methods.

141 relapsing-remitting MS and 69 healthy controls (HC) with baseline and 1-year 3D T1-weighted, T2-weighted and diffusion weighted (DW) MRI were collected from the Italian Neuroimaging Network Initiative. From DWI, fractional anisotropy (FA) maps were derived to be used with T1-weighted MRI, as input for the FSL-MIST multimodal segmentation. FSL-FIRST v5.0.9 and Freesurfer v6.0 were also compared, both at baseline and at follow-up. The agreement among the results of the pipelines and the effect sizes in differentiating between MS and HC were assessed. In patients, correlations with age, disease duration, EDSS and T2-hyperintense lesion volume (LV) were evaluated.

At baseline, FIRST and MIST showed the highest significant agreement in the results of thalamic volume (R=0.87, p<0.001), with the highest effect size for MIST (Cohen’s d=1.11). At baseline, FIRST showed the highest significant correlations with age (-0.36, p<0.001), EDSS (R=-0.3, p<0.001, adjusted for age), T2-hyperintense LV (R=-0.4, p<0.001) and disease duration (R=-0.2, p=0.02). At follow-up, MIST showed the lowest variability in estimating thalamic volume changes (TVC) for HC (standard deviation=1.07%) in comparison to the other pipelines, and the highest effect size (Cohen’s d=0.21). In MS patients, only MIST TVC showed a significant correlation (adjusted for age) with T2-hyperintense LV change (R=-0.22, p=0.01).  

We found that the inclusion of FA contrast increased robustness of the longitudinal results and a better capability to detect small variations of thalamic volumes, as shown by MIST results. The advantage of a multimodal approach is also shown by the results of correlations with LV changes for MIST.

Authors/Disclosures
Paolo Preziosa (Ospedale San Raffaele)
PRESENTER
Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Loredana Storelli Loredana Storelli has nothing to disclose.
Elisabetta Pagani Elisabetta Pagani has nothing to disclose.
Patrizia Pantano Patrizia Pantano has nothing to disclose.
Gioacchino Tedeschi, MD (University of Campania "L. Vanvitelli") Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Nicola De Stefano, MD (University of Siena) Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Healthcare KGaA. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic AG. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharma AG. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono S.p.A. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche S.p.A.. The institution of Dr. De Stefano has received research support from Italian MS Society. The institution of Dr. De Stefano has received research support from Merck Healthcare KGaA.
Maria Assunta Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.